Topf Albert, Mirna Moritz, Ohnewein Bernhard, Jirak Peter, Kopp Kristen, Fejzic Dzeneta, Haslinger Michael, Motloch Lukas J, Hoppe Uta C, Berezin Alexander, Lichtenauer Michael
Department of Cardiology, Clinic of Internal Medicine II, Paracelsus Medical University of Salzburg, Salzburg, Austria.
Internal Medicine Department, State Medical University, Zaporozhye, Ukraine.
Front Cardiovasc Med. 2020 Dec 4;7:579567. doi: 10.3389/fcvm.2020.579567. eCollection 2020.
Heart failure is a pathophysiological state, which is still associated with high morbidity and mortality despite established therapies. Diverse well-known biomarkers fail to assess the variety of individual pathophysiology in the context of heart failure. An analysis of prospective, multimarker-specific therapeutic approaches to heart failure based on studies in current literature was performed. A total of 159 screened publications in the field of biomarkers in heart failure were hand-selected and found to be eligible for this study by a team of experts. Established biomarkers of the inflammatory axis, matrix remodeling, fibrosis and oxidative stress axis, as well as potential therapeutic interventions were investigated. Interaction with end organs, such as cardio-hepatic, cardio-renal and cardio-gastrointestinal interactions show the complexity of the syndrome and could be of further therapeutic value. MicroRNAs are involved in a wide variety of physiologic and pathophysiologic processes in heart failure and could be useful in diagnostic as well as therapeutic setting. Based on our analysis by a biomarker-driven approach in heart failure therapy, patients could be treated more specifically in long term with a consideration of different aspects of heart failure. New studies evaluating a multimarker - based therapeutic approach could lead in a decrease in the morbidity and mortality of heart failure patients.
心力衰竭是一种病理生理状态,尽管已有既定的治疗方法,但它仍与高发病率和高死亡率相关。多种知名的生物标志物无法在心力衰竭的背景下评估个体病理生理的多样性。基于当前文献中的研究,对心力衰竭的前瞻性、多标志物特异性治疗方法进行了分析。心力衰竭生物标志物领域共筛选出159篇出版物,由一组专家手工挑选并确定符合本研究要求。对炎症轴、基质重塑、纤维化和氧化应激轴的既定生物标志物以及潜在的治疗干预措施进行了研究。与心-肝、心-肾和心-胃肠等终末器官的相互作用显示了该综合征的复杂性,可能具有进一步的治疗价值。微小RNA参与心力衰竭中多种生理和病理生理过程,在诊断和治疗方面可能有用。基于我们对心力衰竭治疗中生物标志物驱动方法的分析,考虑到心力衰竭的不同方面,患者长期治疗可能会更具针对性。评估基于多标志物治疗方法的新研究可能会降低心力衰竭患者的发病率和死亡率。